Emily Nieves
Founder/CEOCo-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
Browser storage is unavailable. Keep this page open and export your collection before leaving.

Delineate is building AI agents to design better clinical trials faster.
This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential.
We process existing clinical trial research into specialized datasets saving scientists months of effort.
Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Co-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
Co-Founder and CTO of Delineate. Masters thesis in Robotics/AI with 2 research publications. Former technical project manager for high impact digital transformation projects within Skunkworks (Advanced Development) division at Lockheed Martin.
Founded 2024 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.